Evidence map›Paper›PMID 42110757›Full record

ArticleACS omega2026

Multicomponent Lipid Nanoparticles as a Tool to Potentially Improve the Antibiofilm Activity of Resveratrol against MDR Gram-Positive and Gram-Negative Clinical Isolates.

Giulia Di Prima, Maria Rita Tricoli, Nicola Serra, Viviana De Caro, Ignazio Arrigo, Cecilia La Mantia, Paola Di Carlo, Orazia Diquattro, Anna Giammanco, Teresa Fasciana

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Giulia Di PrimaDepartment of Biological, Chemical and Pharmaceutical Sciences and Technologies, University of Palermo, Via Archirafi 32, 90123 Palermo, Italy.ORCID https://orcid.org/0000-0002-3240-2704
Maria Rita TricoliDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties G. D'Alessandro, University of Palermo, Piazza Delle Cliniche, 2, 90127 Palermo, Italy.
Nicola SerraAudiology Unit, Department of Neuroscience, Reproductive Sciences and Dentistry, University of Naples Federico II, Via Pansini 5, 80131 Naples, Italy.
Viviana De CaroDepartment of Biological, Chemical and Pharmaceutical Sciences and Technologies, University of Palermo, Via Archirafi 32, 90123 Palermo, Italy.ORCID https://orcid.org/0000-0002-5186-1244
Ignazio ArrigoDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties G. D'Alessandro, University of Palermo, Piazza Delle Cliniche, 2, 90127 Palermo, Italy.
Cecilia La MantiaDepartment of Precision Medicine in Medical, Surgical and Critical Care (Me.Pre.C.C.), University of Palermo, Via Liborio Giuffrè, 5, 90127 Palermo, Italy.
Paola Di CarloDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties G. D'Alessandro, University of Palermo, Piazza Delle Cliniche, 2, 90127 Palermo, Italy.
Orazia DiquattroLaboratory of Microbiology, A. O. Ospedali Riuniti "Villa Sofia-Cervello", 90100 Palermo, Italy.
Anna GiammancoDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties G. D'Alessandro, University of Palermo, Piazza Delle Cliniche, 2, 90127 Palermo, Italy.
Teresa FascianaDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties G. D'Alessandro, University of Palermo, Piazza Delle Cliniche, 2, 90127 Palermo, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAmong natural compounds suggested as antimicrobials to overcome the increasing phenomenon of multidrug resistance (MDR), resveratrol (3,5,4'-trihydroxystilbene; RSV), a phytoalexin commonly found in food and drinks, can be considered a valid alternative. Despite its potentially useful antimicrobial action, orally administered RSV fails in efficacy due to several drawbacks (e.g., first pass effect metabolism, instability, poor water solubility), whereas targeted administration could potentially allow efficacious RSV concentrations against infectious diseases. Additionally, RSV clinical use today is restricted due to low stability and solubility, issues that can be overcome by embedding RSV into lipid-based nanocarriers. Recently, ad hoc designed multicomponent lipid nanoparticles loaded with RSV (mLNP-RSV) were optimized and characterized, showing promising preliminary antibiofilm properties.

methodsIn this work, the mLNP-RSV was deeply investigated to assess its potential use for the therapy of Gram-positive and Gram-negative MDR infections. Their antibiofilm action against ATCC 12972

resultsThe administration of free RSV 16 μg/mL determined a biofilm production inhibition of 35.6% and 62.1% for ATCC 12972

conclusionsThese findings suggest the potential of the proposed nanosystem to address RSV limitations while supporting its therapeutic action, indicating that mLNP-RSV could serve as a promising tool for the treatment of MDR infections.

Identifiers

PMID42110757
PMCPMC13150613

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.